IGF-1 LR3 Research: Structure, Evidence and COA Review
IGF-1 LR3 research requires a distinction between molecular identity, biological activity in a specific experimental system, and the analytical results for an individual batch. A variant name or purity percentage cannot establish all three.
For Research Use Only. Not for human or veterinary use.
What is IGF-1 LR3?
Long R3 IGF-I, commonly written IGF-1 LR3, is an IGF-I analogue with an N-terminal extension of 13 amino acids and an arginine substitution for glutamate at position 3 of the IGF-I sequence. The structural description is reported in the bovine immune-cell study listed below. Keep the exact variant name in procurement records: results for native IGF-I or another analogue should not be relabeled as LR3 evidence.
Why do IGF-binding proteins matter?
IGF-binding proteins, abbreviated IGFBPs, are relevant to interpreting ligand availability and cellular responses. A granulosa-cell study described Long R3 IGF-I as having low IGFBP affinity and observed differences from native IGF-I in the production of binding proteins. That observation belongs to the studied system; it does not establish one binding-affinity multiplier for every IGFBP or assay.
When reviewing a paper, distinguish a binding measurement from a downstream cellular endpoint. A larger response in one assay does not by itself demonstrate stronger receptor binding or longer persistence in another system.
What do comparative studies establish?
The bovine immune-cell study compared native IGF-I, DES(1–3) and Long R3 using different cellular readouts. Their relative responses were not identical across the endpoints examined. Separately, a study of porcine granulosa-cell subpopulations reported that responses to IGF-I analogues depended on the cell population and collection conditions. These findings support a model-specific reading of the evidence, rather than a universal ranking of the variants.
Can a universal half-life be assigned?
This guide does not assign LR3 a universal 20–30-hour half-life. A duration claim needs a directly relevant pharmacokinetic study identifying the material, model, sampling method and conditions. Activity observed during cell culture, stability in a container and circulating half-life are different measurements. One cannot be substituted for another.
How to review an LR3 batch
- Traceability: match the product designation and lot number to the report.
- Identity: inspect the method and reported result. An intact-mass match alone should not be described as complete sequence confirmation.
- Purity: read the chromatographic method, result and supporting data. A purity percentage is not a functional-activity result.
- Additional tests: check whether endotoxin, sterility or other relevant attributes were actually measured. Do not infer them from a purity result or from the presence of a COA.
- Handling records: use the supplier’s documented storage instructions and retain receipt and storage records. Do not infer shelf life from an activity claim.
Questions to resolve before interpreting results
Does the reference examine LR3 itself? Is the experimental matrix comparable? Are the comparator and endpoint identified? Does the report document chemical characteristics, functional activity, or both? These questions help keep published findings separate from assumptions about a purchased lot.
Related research and documentation
For a side-by-side discussion of variants, read IGF-1 LR3 vs DES(1–3). Review the IGF-1 LR3 product specifications and locate the relevant lot in the COA library. Only tests documented for that lot should be treated as completed tests.
Primary research references
- Effects of IGF-I and its analogues on bovine immune-cell assays — structural descriptions and assay-specific comparisons.
- Insulin and IGFs stimulate IGF-binding protein production by ovarian granulosa cells — binding-protein context in a cellular model.
- Differential responses of porcine granulosa-cell subpopulations to IGF-1 analogues — dependence on cell population and experimental conditions.